Comparative Pharmacology
Head-to-head clinical analysis: LEVETIRACETAM versus VIGADRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVETIRACETAM versus VIGADRONE.
LEVETIRACETAM vs VIGADRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levetiracetam's precise mechanism of action is unknown. It binds to synaptic vesicle protein 2A (SV2A), which may modulate neurotransmitter release and reduce neuronal excitability. It also inhibits N-type calcium channels and reduces calcium influx, contributing to antiepileptic effects.
Irreversible inhibitor of GABA transaminase (GABA-T), leading to increased brain concentrations of gamma-aminobutyric acid (GABA).
500-1500 mg PO/IV BID; initial 500 mg BID, titrate by 500 mg BID every 2 weeks as tolerated; maximum 3000 mg/day.
Adults: 500 mg orally twice daily, may increase by 500 mg/day every week; maximum 1500 mg twice daily.
None Documented
None Documented
Clinical Note
moderateLevetiracetam + Venlafaxine
"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Venlafaxine."
Clinical Note
moderateLevetiracetam + Nefazodone
"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Nefazodone."
Clinical Note
moderateLevetiracetam + Ranolazine
"The serum concentration of Ranolazine can be increased when it is combined with Levetiracetam."
Clinical Note
moderateLevetiracetam + Stiripentol
6–8 hours in adults; prolonged to 10–11 hours in mild-to-moderate renal impairment (CrCl 30–50 mL/min) and 16–24 hours in severe impairment (CrCl <30 mL/min); neonates up to 16 hours.
Terminal elimination half-life: 5-7 hours in young adults; 12-15 hours in elderly; therapeutic steady-state achieved within 2-3 days.
Primarily renal (66% unchanged, 27% as inactive metabolite); minimal fecal (<2%).
Renal: 70% unchanged; hepatic metabolism: 20% (primarily via CYP4A7, not CYP450); fecal: <5%.
Category A/B
Category C
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Stiripentol."